Research on the Influence of Radiotherapy-related Genes on Immune Infiltration, Immunotherapy Response and Prognosis in Melanoma Based on Multi-omics

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Dec 17

PMID 39687627

Authors

Yujing Shi

Wantong Zhao

Yuanjian Ding

Xiaolin Ge

Mengyang Ju

Affiliations

Soon will be listed here.

Abstract

Background: Skin cutaneous melanoma (SKCM) is a significant oncological challenge due to its aggressive nature and poor treatment outcomes. This study explores the comprehensive effects of radiotherapy (RT) in SKCM, focusing on cell signaling pathways, immune infiltration, immune gene correlations, immunotherapy response, and prognosis.

Methods: Using the Cancer Genome Atlas (TCGA) database, differentially expressed genes (DEGs) in SKCM patients undergoing RT were identified. A risk score model based on these DEGs was developed to assess the effects of RT-related genes on drug sensitivity, immune cell infiltration, immunotherapy response, and prognosis through multi-omics analysis. Human melanoma cells UACC62 and UACC257 were irradiated with 8 Gy gamma ray to establish an model, verifying the impact of radiotherapy on gene expression.

Results: The risk score demonstrated significant prognostic value and emerged as an independent prognostic factor. miRNA-mRNA and transcription factor regulatory networks underscored its clinical significance. Four key genes were identified: DUSP1, CXCL13, SLAMF7, and EVI2B. Analysis of single-cell and immunotherapy datasets indicated that these genes enhance immune response and immunotherapy efficacy in melanoma patients. PCR results confirmed that gamma rays increased the expression of these genes in human melanoma cells UACC62 and UACC257.

Conclusion: Using a multi-omics approach, we analyzed and validated the impact of RT on the immune landscape of melanoma patients. Our findings highlight the critical role of RT-related genes in predicting SKCM prognosis and guiding personalized therapy strategies, particularly in the context of immunotherapy. These contribute to understanding the role of radiotherapy combined with immunotherapy in melanoma.

References

Chen Z, Luo Z, Zhang D, Li H, Liu X, Zhu K . TIGER: A Web Portal of Tumor Immunotherapy Gene Expression Resource. Genomics Proteomics Bioinformatics. 2022; 21(2):337-348. PMC: 10626175. DOI: 10.1016/j.gpb.2022.08.004. View

Ralli M, Botticelli A, Visconti I, Angeletti D, Fiore M, Marchetti P . Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. J Immunol Res. 2020; 2020:9235638. PMC: 7338969. DOI: 10.1155/2020/9235638. View

Kundra R, Zhang H, Sheridan R, Sirintrapun S, Wang A, Ochoa A . OncoTree: A Cancer Classification System for Precision Oncology. JCO Clin Cancer Inform. 2021; 5:221-230. PMC: 8240791. DOI: 10.1200/CCI.20.00108. View

Kalaora S, Nagler A, Wargo J, Samuels Y . Mechanisms of immune activation and regulation: lessons from melanoma. Nat Rev Cancer. 2022; 22(4):195-207. DOI: 10.1038/s41568-022-00442-9. View

OConnell P, Hyslop S, Blake M, Godbehere S, Amalfitano A, Aldhamen Y . SLAMF7 Signaling Reprograms T Cells toward Exhaustion in the Tumor Microenvironment. J Immunol. 2020; 206(1):193-205. PMC: 7855551. DOI: 10.4049/jimmunol.2000300. View

Long G, Swetter S, Menzies A, Gershenwald J, Scolyer R . Cutaneous melanoma. Lancet. 2023; 402(10400):485-502. DOI: 10.1016/S0140-6736(23)00821-8. View

Postow M, Callahan M, Barker C, Yamada Y, Yuan J, Kitano S . Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med. 2012; 366(10):925-31. PMC: 3345206. DOI: 10.1056/NEJMoa1112824. View

Gershenwald J, Scolyer R, Hess K, Sondak V, Long G, Ross M . Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017; 67(6):472-492. PMC: 5978683. DOI: 10.3322/caac.21409. View

Tagliaferri L, Lancellotta V, Fionda B, Mangoni M, Casa C, Di Stefani A . Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive review. Hum Vaccin Immunother. 2021; 18(3):1903827. PMC: 9122308. DOI: 10.1080/21645515.2021.1903827. View

10.

Mendenhall W, Amdur R, Grobmyer S, George Jr T, Werning J, Hochwald S . Adjuvant radiotherapy for cutaneous melanoma. Cancer. 2008; 112(6):1189-96. DOI: 10.1002/cncr.23306. View

11.

Schaue D, Ratikan J, Iwamoto K, McBride W . Maximizing tumor immunity with fractionated radiation. Int J Radiat Oncol Biol Phys. 2012; 83(4):1306-10. PMC: 3337972. DOI: 10.1016/j.ijrobp.2011.09.049. View

12.

Ma Y, Zheng S, Xu M, Chen C, He H . Establishing and Validating an Aging-Related Prognostic Signature in Osteosarcoma. Stem Cells Int. 2023; 2023:6245160. PMC: 10643040. DOI: 10.1155/2023/6245160. View

13.

Zhang C, Shen H, Yang T, Li T, Liu X, Wang J . A single-cell analysis reveals tumor heterogeneity and immune environment of acral melanoma. Nat Commun. 2022; 13(1):7250. PMC: 9700682. DOI: 10.1038/s41467-022-34877-3. View

14.

Singh M, Altameemi S, Lares M, Newton M, Setaluri V . Role of dual specificity phosphatases (DUSPs) in melanoma cellular plasticity and drug resistance. Sci Rep. 2022; 12(1):14395. PMC: 9399232. DOI: 10.1038/s41598-022-18578-x. View

15.

Garutti M, Bruno R, Polesel J, Pizzichetta M, Puglisi F . Role of tumor-infiltrating lymphocytes in melanoma prognosis and treatment strategies: A systematic review and meta-analysis. Heliyon. 2024; 10(12):e32433. PMC: 11341338. DOI: 10.1016/j.heliyon.2024.e32433. View

16.

Saiag P, Molinier R, Roger A, Boru B, Otmezguine Y, Otz J . Efficacy of Large Use of Combined Hypofractionated Radiotherapy in a Cohort of Anti-PD-1 Monotherapy-Treated Melanoma Patients. Cancers (Basel). 2022; 14(17). PMC: 9454723. DOI: 10.3390/cancers14174069. View

17.

Jarosz-Biej M, Smolarczyk R, Cichon T, Kulach N . Tumor Microenvironment as A "Game Changer" in Cancer Radiotherapy. Int J Mol Sci. 2019; 20(13). PMC: 6650939. DOI: 10.3390/ijms20133212. View

18.

Karasarides M, Cogdill A, Robbins P, Bowden M, Burton E, Butterfield L . Hallmarks of Resistance to Immune-Checkpoint Inhibitors. Cancer Immunol Res. 2022; 10(4):372-383. PMC: 9381103. DOI: 10.1158/2326-6066.CIR-20-0586. View

19.

Farhangnia P, Ghomi S, Mollazadehghomi S, Nickho H, Akbarpour M, Delbandi A . SLAM-family receptors come of age as a potential molecular target in cancer immunotherapy. Front Immunol. 2023; 14:1174138. PMC: 10213746. DOI: 10.3389/fimmu.2023.1174138. View

20.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View